Last mentioned: Mar 22, 2026
Collaborative Intelligence
Physicians must adapt to a role as synthesizers of AI data rather than sole gatekeepers of medical truth.
Type B FDA Meeting Target
Planned follow-up to define Phase III and regulatory path for AMT-130.
AMT-260 Data Readout
Expected clinical data from Phase I/IIa epilepsy study in H1 2026.
DOJ Missouri Filing
DOJ quietly asks the Missouri court to pause proceedings pending FDA review.
Legislative Action
Sen. Josh Hawley introduces a Senate bill to outright ban the abortion pill.
Earnings Call
Management confirms CMS reimbursement rate of $897 and 2025 assay expansion.
Type A FDA Meeting
Discussed AMT-130 approval pathway; alignment not yet reached.
Louisiana Precedent
DOJ unsuccessfully asks Louisiana to pause its separate anti-abortion lawsuit.
FDA Submission
510(k) premarket notification submitted for Lucent AD Complete.
Q4 2025 Close
Quanterix reports $43.9M in revenue with 25% YoY growth.
Fiscal Year End
Closed 2025 with $622.5 million in liquidity.
Amended Complaint
AG Catherine Hanaway adds claims that mail-order drugs are dangerous without in-person visits.
Lawsuit Filed
Missouri, Kansas, and Idaho file suit against the FDA over mifepristone regulations.
The Regulatory Gap
Widespread clinical use of generative AI occurs despite a lack of formal FDA approval or institutional oversight.
The LLM Explosion
Launch of ChatGPT and Claude brings interactive AI to the general public and clinicians' smartphones.
The Primitive AI Era
AI used for back-end tasks like reading EKGs, interpreting imaging, and EHR clinical alerts.
The integration of large language models like ChatGPT and Claude into clinical settings is fundamentally altering the traditional physician-patient relationship. Bioethicist Dr. John Lantos warns that the transition from 'invisible' diagnostic AI to 'visible' interactive AI is eroding the historical authority of doctors in a regulatory vacuum.
The U.S. Department of Justice has requested a federal court in Missouri to pause or dismiss a lawsuit targeting the FDA's approval of mifepristone, citing an ongoing internal agency review. This move reflects a strategic effort by the administration to manage high-stakes litigation over medication abortion and telehealth access ahead of the 2026 midterms.
Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA's handling of biologic therapy applications for rare diseases, specifically targeting Duchenne muscular dystrophy. The probe follows a direct consultation with FDA Commissioner Marty Makary regarding perceived regulatory barriers for life-saving treatments.
A high-ranking FDA official is reportedly attempting to recruit Dr. Tracy Beth Hoeg, a vocal advocate for stricter antidepressant warnings, to a key agency role. The move signals a potential shift in how the FDA evaluates long-term psychiatric drug risks and has raised internal concerns regarding hiring protocols.
Quanterix reported a 25% year-over-year revenue increase to $43.9 million in Q4 2025, driven by a surge in diagnostics partner revenue and critical regulatory milestones. The company achieved a commercial breakthrough with a $897 CMS reimbursement rate for its Lucent AD Complete test, positioning it for large-scale clinical adoption.
uniQure reported a strong cash position of $622.5 million, extending its operational runway into 2029. While the company continues to seek regulatory alignment with the FDA for its Huntington’s disease candidate AMT-130, it is advancing clinical trials for epilepsy and Fabry disease with key data readouts expected in 2026.
A series of recent clinical studies have directly challenged the public health assertions made by Robert F. Kennedy Jr. regarding vaccines, Tylenol, and antidepressants. These findings underscore a growing tension between evidence-based medicine and the policy platform of the potential future leadership at the Department of Health and Human Services.
This page surfaces every story mentioning FDA across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where FDA was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |